Coagulopathy in critically ill patients - Part 1: Platelet disorders

Chest

Volumn 136, Issue 6, 2009, Pages 1622-1630

  Rice, Todd W ^a   Wheeler, Arthur P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CLOPIDOGREL; COTRIMOXAZOLE; CYCLOSPORIN; DAPTOMYCIN; DESMOPRESSIN; DIGOXIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUCONAZOLE; FUROSEMIDE; GANCICLOVIR; HALOPERIDOL; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; LINEZOLID; MEROPENEM; MORPHINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; RIFAMPICIN; THROMBIN INHIBITOR; UNINDEXED DRUG; VALGANCICLOVIR; VANCOMYCIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; HELLP SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 73149103225     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2534     Document Type: Article

References (71)

1. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28:1871-1876
2. Strauss R, Wehler M, Mehler K, et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30:1765-1771
3. Baughman RP, Lower EE, Flessa HC, et al. Thrombocytopenia in the intensive care unit. Chest 1993; 104:1243-1247
4. Bonfiglio MF, Traeger SM, Kier KL, et al. Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 1995; 29:835-842
5. Chakraverty R, Davidson S, Peggs K, et al. The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996; 93:460-463
6. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005; 20:348-353
7. Stephan F, Hollande J, Richard O, et al. Thrombocytopenia in a surgical ICU. Chest 1999; 115:1363-1370
8. Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors for thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997; 31:285-289
9. Akca S, Haji-Michael P, De MA, et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30:753-756
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
11. Mavrommatis AC, Theodoridis T, Orfanidou A, et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000; 28:451-457
12. Sharma B, Sharma M, Majumder M, et al. Thrombocytopenia in septic shock patients: a prospective observational study of incidence, risk factors, and correlation with clinical outcome. Anaesth Intensive Care 2007; 35:874-880
13. Mercer KW, Macik B, Williams ME. Hematologic disorders in critically ill patients. Semin Respir Crit Care Med 2006; 27:286-296
14. Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000; 162:347-351
15. Oppenheim-Eden A, Glantz L, Eidelman LA, et al. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999; 25:63-67
16. Contreras M. Consensus conference on platelet transfusion: final statement. Vox Sang 1998; 75:173-174
17. British Society for Haematology. Guidelines for use of platelet transfusions. Br J Haematol 2003; 122:10-23
18. Arnold DM, Crowther MA, Cook RJ, et al. Utilization of platelet transfusions in the intensive care unit: indications, transfusions triggers, and platelet count responses. Transfusion 2006; 46:1286-1291
19. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management. Clin Haematol 1978; 7:523-539
20. Rebulla P. Revisitation of the clinical indications for the transfusion of platelet concentrates. Rev Clin Exp Hematol 2001; 5:288-310
21. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266:905-909
22. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-1875
23. Sagmeister M, Oec L, Gmür J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93:3124-3126
24. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
25. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31(suppl):S85-S93
26. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? Crit Care Med 2006; 34(suppl):S170-S173
27. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533-538
28. Shalansky SJ, Verma AK, Levine M, et al. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy 2002; 22:803-813
29. Stephan F, de Montblanc J, Cheffi A, et al. Thrombocytopenia in critically ill surgical patients: a case-control study evaluating attributable mortality and transfusion requirements. Crit Care 1999; 3:151-158
30. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important sub-groups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
31. Drews RE. Critical issues in hematology: anemia, thrombo-cytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003; 24:607-622
32. Berkman N, Michaeli Y, Or R, et al. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991; 36:195-201
33. George JN, Raskob GE. Idiopathic thrombocytopenic pur-pura: diagnosis and management. Am J Med Sci 1998; 316:87-93
34. Bogdonoff DL, Williams ME, Stone DJ. Thrombocytopenia in the critically ill patient. J Crit Care 1990; 5:186-205
35. Martin JF, Daniel TD, Towbridge EA. Acute and chronic changes in platelet volume and count after cardiopulmonary bypass induced thrombocytopenia in man. Thromb Haemost 1987; 57:55-58
36. Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001; 112:851-862
37. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic pur-pura. N Engl J Med 1998; 339:1585-1594
38. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600
39. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927-1935
40. Singer K. Thrombotic thrombocytopenic purpura. Adv Intern Med 1954; 6:195-234
41. Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356:904-910
42. Aster RH, Bougie DW. Drug-induced immune thrombocy-topenia. N Engl J Med 2007; 357:580-587
43. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129:886-890
44. Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21:685-696
45. Aster RH. Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 2000; 37:229-238
46. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the Society of Hematology. Blood 1996; 88:3-40
47. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127(suppl):53S-59S
48. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355:809-817
49. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 2005; 94:132-135
50. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710-2715
51. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99:779-781
52. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101:2955-2959
53. Warkentin TE, Sheppard JAI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146:341-346
54. Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006; 43(suppl):S59-S63
55. Wolberg AS, Meng ZH, Monroe DM, et al. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221-1228
56. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45:645-657
57. Peck-Radosavljevic M, Wichlas M, Azcherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795-801
58. Clark DA, Krantz SB. Effects of ethanol on cultured human megakaryocytic progenitors. Exp Hematol 1986; 14:951-954
59. Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-698
60. Gerson S, Kaplan S, Bruss S, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-2726
61. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51(suppl):ii45-ii53
62. Dempfle CE, Borggrefe M. Point of care coagulation tests in critically ill patients. Semin Thromb Hemost 2008; 34:445-450
63. Dickinson KJ, Troxler M, Homer-Vanniasinkam S. The surgical application of point-of-care haemostasis and platelet function testing. Br J Surg 2008; 95:1317-1330
64. Ingerselv J, Sorensen B, Castaman G, et al. New approaches in the measurement of coagulation. Haemophilia 2008; 14(suppl):104-112
65. Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3:138-153
66. Stewart JH, Castaldi PA. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Q J Med 1967; 36:409-423
67. Watson AJ, Keogh JA. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 1982; 32:49-52
68. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308:8-12
69. Livio M, Mannucci PM, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315:731-735
70. Janson PA, Jubelirer SJ, Weinstein MJ, et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303:1318-1322
71. Robertson J, Lillicrap D, James PD. Von Willebrand disease. Pediatr Clin North Am 2008; 55:377-392